The rapid development of drug resistance to lenacapavir when used as the only active drug as part of rescue therapy against multidrug resistant HIV-2 was reported in a brief case review in Clinical Infectious Diseases.
Thomas Montrouge and colleagues reported on eight people enrolled in the French ANRS-MIE CO5 HIV-2 cohort who had received lenacapavir on named patient access.
Read the full report by Simon Collins, HIV i-Base here.
Source : HIV i-Base
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.